An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets

Summary

Platelet cold agglutinins (PCA) cause pseudothrombocytopenia, spurious thrombocytopenia due to ex vivo platelet clumping, complicating clinical diagnosis, but mechanisms and consequences of PCA are not well defined. Here, we characterised an atypical immunoglobulin (Ig)M PCA in a 37-year-old woman with lifelong bleeding and chronic moderate thrombocytopenia, that induces activation and aggregation of autologous or allogeneic platelets via interaction with platelet glycoprotein (GP)VI. Patient temperature-dependent pseudothrombocytopenia was EDTA-independent, but was prevented by integrin αIIbβ3 blockade. Unstimulated patient platelets revealed elevated levels of bound IgM, increased expression of activation markers (P-selectin and CD63), low GPVI levels and abnormally high thromboxane (TX)A₂ production. Patient serum induced temperature- and αIIbβ3-dependent decrease of platelet count in allogeneic donorcitrated platelet-rich plasma (PRP), but not in PRP from Glanzmann’s thrombasthenia or afibrinogenaemia patients. In allogeneic platelets, patient plasma induced shape change, P-selectin and CD63 expression, ¹⁴C-serotonin release, and TXA₂ production. Activation was not inhibited by aspirin, cangrelor or blocking anti-Fc receptor (FcγRIIA) antibody, but was abrogated by inhibitors of Src and Syk, and by a soluble GPVI-Fc fusion protein. GPVI-deficient platelets were not activated by patient plasma. These data provide the first evidence for an IgM PCA causing platelet activation/aggregation via GPVI. The PCA activity persisted over a five-year follow-up period, supporting a causative role in patient chronic thrombocytopenia and bleeding.

Keywords

Cold agglutinin - human platelet antigens - platelet activation - platelet glycoprotein VI - thrombocytopenia - plasma and platelet lipid composition

• References

• 1 Bizzaro N. EDTA-dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 1995; 50: 103-109.
• 2 Schuff-Werner P, Steiner M, Fenger S. et al. Effective estimation of correct platelet counts in pseudothrombocytopenia using an alternative anticoagulant based on magnesium salt. Br J Haematol 2013; 162: 684-692.
• 3 Lippi G, Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med 2012; 50: 1281-1285.
• 4 Onder O, Weinstein A, Hoyer LW. Pseudothrombocytopenia caused by platelet agglutinins that are reactive in blood anticoagulated with chelating agents. Blood 1980; 56: 177-182.
• 5 Cunningham VL, Brandt JT. Spurious thrombocytopenia due to EDTA-independent cold-reactive agglutinins. Am J Clin Pathol 1992; 97: 359-362.
• 6 Kuijpers RW, Ouwehand WH, Peelen W. et al. Thrombocytopenia due to platelet glycoprotein IIb/IIIa-reactive autoantibodies non-reactive with platelets from EDTA blood. Vox Sang 1992; 63: 119-121.
• 7 Schimmer A, Mody M, Sager M. et al. Platelet cold agglutinins: a flow cytometric analysis. Transfus Sci 1998; 19: 217-224.
• 8 Hoyt RH, Durie BG. Pseudothrombocytopenia induced by a monoclonal IgM kappa platelet agglutinin. Am J Hematol 1989; 31: 50-52.
• 9 Takeuchi T, Yoshioka K, Hori A. et al. Cytomegalovirus mononucleosis with mixed cryoglobulinemia presenting transient pseudothrombocytopenia. Intern Med 1993; 32: 598-601.
• 10 Hsieh AT, Chao TY, Chen YC. Pseudothrombocytopenia associated with infectious mononucleosis. Arch Pathol Lab Med 2003; 127: e17-18.
• 11 Wenzel F, Lasshofer R, Rox J. et al. Transient appearance of postoperative EDTA-dependent pseudothrombocytopenia in a patient after gastrectomy. Platelets 2011; 22: 74-76.
• 12 Gillis S, Eisenberg ME, Shapira MY. et al. Pseudothrombocytopenia after allogeneic non-myeloablative stem cell transplantation. Isr Med Assoc J 2003; 05: 671-673.
• 13 Sane DC, Damaraju LV, Topol EJ. et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36: 75-83.
• 14 Casonato A, Fabris F, Girolami A. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease patient. Eur J Haematol 1990; 45: 36-42.
• 15 Albersen A, Porcelijn L, Schilders J. et al. Sunitinib-associated pseudothrombocytopenia induced by IgM antibody. Platelets 2013; 24: 566-570.
• 16 Nilsson T, Norberg B. Thrombocytopenia and pseudothrombocytopenia: a clinical and laboratory problem. Scand J Haematol 1986; 37: 341-346.
• 17 Lau LG, Chng WJ, Liu TC. Transfusion medicine illustrated. Unnecessary transfusions due to pseudothrombocytopenia. Transfusion 2004; 44: 801.
• 18 Solanki DL, Blackburn BC. Spurious leukocytosis and thrombocytopenia. A dual phenomenon caused by clumping of platelets in vitro. J Am Med Assoc 1983; 250: 2514-2515.
• 19 Sharma A, Pinto Pereira LM, Capildeo K. et al. Steroid-induced iatrogenic disease after treating for pseudothrombocytopenia. Clin Appl Thromb Hemost 2011; 17: 100-102.
• 20 Bizzaro N. Platelet cold agglutinins and cardiac surgery hypothermia. Am J Hematol 1999; 60: 80.
• 21 Wilkes NJ, Smith NA, Mallett SV. Anticoagulant-induced pseudothrombocytopenia in a patient presenting for coronary artery bypass grafting. Br J Anaesth 2000; 84: 640-642.
• 22 Nair SK, Shah R, Petko M. et al. Pseudothrombocytopenia in cardiac surgical practice. Interact Cardiovasc Thorac Surg 2007; 06: 565-566.
• 23 Kocum TH, Katircibasi TM, Sezgin AT. et al. An unusual cause of mismanagement in an acute myocardial infarction case: pseudothrombocytopenia. Am J Emerg Med 2008; 26: 740e1-2.
• 24 Schwarz M, Meade G, Stoll P. et al. Conformation-specific blockade of the inte-grin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006; 99: 25-33.
• 25 Al-Tamimi M, Mu FT, Arthur JF. et al. Anti-glycoprotein VI monoclonal antibodies directly aggregate platelets independently of FcgammaRIIa and induce GPVI ectodomain shedding. Platelets 2009; 20: 75-82.
• 26 Miura Y, Takahashi T, Jung SM. et al. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem 2002; 277: 46197-46204.
• 27 Al-Tamimi M, Mu FT, Moroi M. et al. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009; 20: 143-149.
• 28 Plaza EM, Cespedes P, Fernandez H. et al. Quality assessment of buffy-coat-derived leucodepleted platelet concentrates in PAS-plasma, prepared by the OrbiSac or TACSI automated system. Vox Sang 2014; 106: 38-44.
• 29 Guerrero JA, Lozano ML, Castillo J. et al. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 2005; 03: 369-376.
• 30 Holmsen H, Dangelmaier CA. Measurement of secretion of serotonin. Methods Enzymol 1989; 169: 205-210.
• 31 Plaza EM, Lozano ML, Guiu IS. et al. Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system. Blood Transfus 2012; 10: 480-489.
• 32 Justel A, Peña D, Zamar R. A multivariate Kolmogorov-Smirnov test of goodness of fit. Stat Probabil Lett 1997; 35: 251-259.
• 33 Navarro-Nunez L, Teruel R, Anton AI. et al. Rare homozygous status of P43 beta1-tubulin polymorphism causes alterations in platelet ultrastructure. Thromb Haemost 2011; 105: 855-863.
• 34 Bergmeier W, Stefanini L. Platelet ITAM signalling. Curr Opin Hematol 2013; 20: 445-450.
• 35 Brandt KJ, Kruithof EK, de Moerloose P. Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res 2013; 132: 408-413.
• 36 Iturbe T, Espanol I, Sanchez A. et al. [Enoxaparin-induced thrombocytopenia with associated arterial and venous thrombosis]. Med Clin 2011; 136: 38-39.
• 37 Al-Tamimi M, Grigoriadis G, Tran H. et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011; 117: 3912-3920.
• 38 Gardiner EE, Al-Tamimi M, Mu FT. et al. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 2008; 6: 1175-1182.
• 39 Al-Tamimi M, Gardiner EE, Thom JY. et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 2011; 42: 498-500.
• 40 Nagler M, Keller P, Siegrist D. et al. A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon. BMC Clin Pathol 2014; 14: 19.
• 41 Kumar TB, Bhardwaj N. Platelet cold agglutinins and thrombocytopenia: A diagnostic dilemma in the intensive care unit. J Anaesthesiol Clin Pharmacol 2014; 30: 89-90.
• 42 Casonato A, Bertomoro A, Pontara E. et al. EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. J Clin Pathol 1994; 47: 625-630.
• 43 Ryo R, Sugano W, Goto M. et al. Platelet release reaction during EDTA-induced platelet agglutinations and inhibition of EDTA-induced platelet agglutination by anti-glycoprotein II b/III a complex monoclonal antibody. Thromb Res 1994; 74: 265-272.
• 44 Klimovich VB. IgM and its receptors: structural and functional aspects. Biochemistry 2011; 76: 534-549.
• 45 Al-Tamimi M, Arthur JF, Gardiner E. et al. Focusing on plasma glycoprotein VI. Thromb Haemost 2012; 107: 648-655.
• 46 Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007; 139: 363-372.
• 47 Andrews RK, Arthur JF, Gardiner EE. Targeting GPVI as a novel antithrombotic strategy. J Blood Med 2014; 05: 59-68.
• 48 Greinacher A. Platelet activation by heparin. Blood 2011; 117: 4686-4687.
• 49 Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev 2008; 22: 1-15.